Pharmacogenomics for Prader-Willi syndrome: caregiver interest and planned utilization
Yael Bar-Peled1, Jessica J Denton1, Jaimie L Richards2,3
1Department of Clinical & Diagnostic Sciences, University of Alabama at Birmingham, AL 35294, USA.
None:
Aim: The study aim was to determine caregiver interest and planned utilization of pharmacogenomic (PGx) results for their child with Prader-Willi syndrome. Methods: Caregivers consented to PGx testing for their child and completed a survey before receiving results. Results: Of all caregivers (n = 48), 93.8% were highly interested in their child's upcoming PGx results. Most (97.9%) planned to share results with their child's medical providers. However, only 47.9% of caregivers were confident providers would utilize the PGx results. Conclusion: Caregivers are interested in utilizing PGx but are uncertain providers will use these results in their child's care. More information about provider comfort with PGx utilization is needed to understand how PGx education would benefit providers and ultimately patients with PGx results.
Related Concept Videos
Human Genetics
The complex relationship between genetics and psychology is observable through common biological components such...
Analysis of Population Pharmacokinetic Data
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...
Behavioral Genetics and Its Designs
The primary methodologies used in behavior genetics include family studies, twin studies, and adoption studies, each providing unique...
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...
Pharmacovigilance
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...


